Volvo EX90 Electric SUV Will Feature Seoul Semiconductor’s SunLike LED Lighting
18.4.2023 16:00:00 EEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a global optical semiconductor company, has announced that the new Volvo EX90 Electric SUV will feature its SunLike LED lights. This is the first application of the SunLike technology with sun spectrum in production vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005618/en/
Volvo EX90 featuring the SunLike technology (Left) / Comparative graph of color gamuts between SunLike and general LEDs (Right) (Graphic: Business Wire)
SunLike, developed and mass-produced by Seoul Semiconductor for the first time in the world, is a healthy light technology that replicates natural light, protecting the 24-hour biological cycle of a human body. For the past five years, Seoul Semiconductor carried out multiple clinical trials with Harvard University in the United States, the University of Basel in Switzerland, and Seoul National University in Korea, confirming that the use of the solar spectrum, SunLike, can make improvements in myopia, regenerate cells, improve memory, and replicate natural colors.
NEARSIGHTEDNESS IMPROVEMENT
Not all lights are the same, and not all lightings are the same. The closer it is to natural light, the better it is. Light is a mass of particles with energy, so the longer our eyes are exposed to high levels of blue light with high energy, there is a greater chance of damaging our photoreceptor cells and developing myopia. This is why children in Asia who spend more time indoors than outdoors under natural light have a high prevalence of myopia.
According to the “Recovery From Form-Deprivation Myopia in Chicks Is Dependent Upon the Fullness and Correlated Color Temperature of the Light Spectrum(2020)” by Singapore Eye Research Institute (SERI), myopia can be improved by using SunLike.
CELL REPRODUCTION
Natural light affects sleep as well. Evening sunlight promotes the secretion of melatonin which helps to sleep. They say more than 70% of our 60 trillion body cells regenerate while we sleep. Seoul Semiconductor confirmed through the “Effect of daylight LED on visual comfort, melatonin, mood, waking performance and sleep (2019)” conducted by the University of Basel in Switzerland that SunLike lighting improves sleep quality compared to conventional LEDs.
MEMORY IMPROVEMENT
Getting a good night sleep reduces the possibility of building up toxins in the brain, improving memory and concentration. Seoul Semiconductor confirmed through the “Daytime Exposure to Short Wavelength-Enriched Light Improves Cognitive Performance in Sleep-Restricted College-Aged Adults (2021)” conducted by Harvard Medical School that problem-solving skills improved by 5% and speed increased by 3.2 folds when SunLike lighting was used.
COLOR REPLICATION
Conventional LED with CRI 90 have a 90% color gamut of 14 colors in high CRI 90 (sunlight 100). However, SunLike has a 95% color gamut of all 99 colors. This means that it is closest to the color seen under natural sunlight.
According to Dan Fidgett, Volvo’s head of materials and colors, “By utilising the spectrum of light emitted from the SunLike LEDs, the progressive materials and interior design of the Volvo EX90 stand out more clearly and without colour distortion” Fidgett also added, “Bringing in SunLike LEDs to the interior of the Volvo EX90 is another illustration of our ambition to bring in innovative technology to deliver a renewed premium in-car experience for our customers”.
For all interior light fixtures of Volvo EX90, SunLike will be installed. Already widely used by large museums and art galleries around the world, SunLike LEDs have been used to reveal the color and texture of Pompeii ruins’ murals in Italy.
N. Kobayashi, SunLike’s key developer and Seoul Semiconductor’s technical advisor (former CEO of TMAT), explains, “SunLike is a differentiated, high-quality ‘healthy lighting’ that has all the benefits of natural light. It is widely being used in various places, such as residential spaces where people rest, hospitals that lack outdoor activities, schools where concentration and vision health are important, horticultural greenhouses that require light, etc”.
In addition to Volvo EX90, SunLike will also equip ‘Polestar 3’ which shares the same technology base.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 18,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. Seoul’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en, YouTube, LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005618/en/
Contact information
Seoul Semiconductor Co., Ltd.
Jinseop Jung
+82-1566-2771
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
